SI-BONE, Inc.

NasdaqGM:SIBN 주식 리포트

시가총액: US$584.5m

SI-BONE 경영진

경영진 기준 점검 2/4

SI-BONE CEO는 Laura Francis, Apr2021 에 임명되었습니다 의 임기는 5.08 년입니다. 총 연간 보상은 $7.45M, 9.2% 급여 및 90.8% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $6.36M 가치에 해당하는 회사 주식의 1.09% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 5.1 년과 15.4 년입니다.

핵심 정보

Laura Francis

최고경영자

US$7.5m

총 보수

CEO 급여 비율9.19%
CEO 재임 기간5.1yrs
CEO 지분 보유율1.1%
경영진 평균 재임 기간5.1yrs
이사회 평균 재임 기간15.4yrs

최근 경영진 업데이트

Recent updates

SIBN: 2026 Guidance And Trauma Partnership Will Support Further Upside

Analysts have kept SI-BONE's price target steady at $22.00, citing only modest tweaks to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions, rather than any major change in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac joint fusion, expanding access to these products through Smith+Nephew's trauma portfolio and SI-BONE's existing sales channel (Key Developments).

SIBN: 2026 Outlook And Pelvic Fixation Partnership Will Support Upside

Analysts now hold their price target for SI-BONE steady at $22.00. This reflects only small tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially shift their overall valuation view.

SIBN: 2026 Revenue Outlook And Pelvic Fixation Deal Will Support Upside

Analysts have held their SI-BONE price target steady at $22.00, with only modest tweaks to assumptions on discount rate, revenue growth, profit margin, and future P/E, reflecting fine tuning rather than a shift in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac (SI) joint fusion, broadening access to these products through Smith+Nephew's trauma channel alongside SI-BONE's existing salesforce (Key Developments).

SIBN: 2026 Revenue Outlook And New Distribution Deal Will Support Upside

Analysts have trimmed their price target for SI-BONE from $23.00 to $22.00, reflecting updated assumptions that include slightly lower revenue growth expectations, a modestly higher profit margin outlook, and a revised forward P/E multiple. What's in the News SI-BONE issued earnings guidance for 2026, projecting worldwide revenue in a range of $228.5 million to $232.5 million, with implied year over year growth guidance of about 14% to 16% (company guidance).

SIBN: Higher 2025 Revenue Guidance Will Support Future Upside Potential

Analysts have maintained their fair value estimate for SI-BONE at $23.00. They made small adjustments to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together support this reaffirmed target.

SIBN: Raised 2025 Revenue Guidance Will Drive Stronger Profitability And Share Price Upside

Analysts have modestly lowered their price target on SI-BONE to 23.00 dollars per share, reflecting a slightly higher discount rate and a marginally lower expected future price to earnings multiple, even as they factor in stronger long term revenue growth prospects. What's in the News SI-BONE raised its 2025 revenue guidance to a range of 198 million to 200 million dollars, up from 195 million to 198 million dollars previously.

SIBN: Raised Revenue Guidance Will Support Stronger Profitability And Share Price Upside

Analysts have raised their price target on SI-BONE from 20 dollars to 23 dollars, citing slightly stronger expectations for revenue growth, profitability, and long term valuation multiples. What's in the News Company raised 2025 revenue guidance to a range of 198 million dollars to 200 million dollars, up from a prior range of 195 million dollars to 198 million dollars, signaling increased confidence in demand trends (company guidance filing) The updated outlook implies faster top line growth than previously anticipated and supports analysts' upward revisions to price targets and long term valuation assumptions (company guidance filing) The narrowing of the revenue guidance range suggests greater visibility into procedure volumes and commercial execution for the remainder of the year (company guidance filing) Valuation Changes The fair value estimate has risen slightly from 20 dollars to 23 dollars per share, reflecting modestly stronger growth and profitability assumptions.

Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 13
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Getting In Cheap On SI-BONE, Inc. (NASDAQ:SIBN) Might Be Difficult

Nov 12
Getting In Cheap On SI-BONE, Inc. (NASDAQ:SIBN) Might Be Difficult

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Jun 26
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

May 09
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Revenues Tell The Story For SI-BONE, Inc. (NASDAQ:SIBN) As Its Stock Soars 30%

May 08
Revenues Tell The Story For SI-BONE, Inc. (NASDAQ:SIBN) As Its Stock Soars 30%

SI-BONE (NASDAQ:SIBN) Has Debt But No Earnings; Should You Worry?

Mar 27
SI-BONE (NASDAQ:SIBN) Has Debt But No Earnings; Should You Worry?
User avatar

TORQ And TNT Will Expand Market Reach In 2025

Strong product launches and a robust innovation pipeline suggest promising future revenue growth and strengthened market positioning.

SI-BONE, Inc. (NASDAQ:SIBN) Looks Just Right With A 26% Price Jump

Jan 19
SI-BONE, Inc. (NASDAQ:SIBN) Looks Just Right With A 26% Price Jump

Market Cool On SI-BONE, Inc.'s (NASDAQ:SIBN) Revenues

Nov 04
Market Cool On SI-BONE, Inc.'s (NASDAQ:SIBN) Revenues

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Sep 25
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark

Apr 01
SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark

Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report

Feb 29
Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Feb 28
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Nov 12
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Aug 09
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Is SI-BONE (NASDAQ:SIBN) A Risky Investment?

Apr 20
Is SI-BONE (NASDAQ:SIBN) A Risky Investment?

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Jan 01
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Sep 24
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

CEO 보수 분석

Laura Francis의 보수는 SI-BONE의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Dec 31 2025US$7mUS$685k

-US$19m

Sep 30 2025n/an/a

-US$22m

Jun 30 2025n/an/a

-US$24m

Mar 31 2025n/an/a

-US$27m

Dec 31 2024US$7mUS$652k

-US$31m

Sep 30 2024n/an/a

-US$37m

Jun 30 2024n/an/a

-US$41m

Mar 31 2024n/an/a

-US$43m

Dec 31 2023US$4mUS$622k

-US$43m

Sep 30 2023n/an/a

-US$44m

Jun 30 2023n/an/a

-US$48m

Mar 31 2023n/an/a

-US$55m

Dec 31 2022US$5mUS$604k

-US$61m

Sep 30 2022n/an/a

-US$65m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$62m

Dec 31 2021US$3mUS$527k

-US$57m

Sep 30 2021n/an/a

-US$51m

Jun 30 2021n/an/a

-US$45m

Mar 31 2021n/an/a

-US$43m

Dec 31 2020US$2mUS$386k

-US$44m

Sep 30 2020n/an/a

-US$44m

Jun 30 2020n/an/a

-US$46m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$2mUS$375k

-US$38m

보상 대 시장: Laura의 총 보수(USD7.45M)는 US 시장에서 비슷한 규모 기업의 평균(USD2.57M)보다 높습니다.

보상과 수익: Laura의 보상은 회사가 적자임에도 증가했습니다.

CEO

Laura Francis (58 yo)

5.1yrs
재임 기간
US$7,453,235
보수

Ms. Laura A. Francis, MBA, has been an Independent Director of Bruker Corporation since February 18, 2025. She serves as Director at Galvanize Therapeutics, Inc. from November 2025. She serves as Chief Exe...

리더십 팀

이름직위재임 기간보수지분
Jeffrey Dunn
Executive Chairman18.1yrsUS$255.35k0.18%
$ 1.1m
Laura Francis
CEO & Director5.1yrsUS$7.45m1.09%
$ 6.4m
Anshul Maheshwari
COO & CFO5.1yrsUS$2.79m0.16%
$ 920.6k
Michael Pisetsky
Chief Business & Legal Affairs Officer9.8yrsUS$2.36m0.30%
$ 1.7m
Anthony Recupero
Advisor9.8yrsUS$2.45m0.36%
$ 2.1m
Scott Yerby
Senior VP of Engineering & CTOno data데이터 없음데이터 없음
Saqib Iqbal
Vice President of Financial Planning & Analysis and Investor Relationsno data데이터 없음데이터 없음
Ian Bailey
Vice President of Product & Marketingless than a year데이터 없음데이터 없음
Daniel Cher
Senior Vice President of Clinical4.9yrs데이터 없음데이터 없음
W. Reckling
Chief Medical Officer & VP of Medical Affairsno data데이터 없음데이터 없음
Nikolas Kerr
Chief Commercial Officer5.1yrs데이터 없음데이터 없음
Jeffrey Zigler
Senior Vice President of Market Access & Reimbursementless than a year데이터 없음데이터 없음
5.1yrs
평균 재임 기간
58yo
평균 나이

경험이 풍부한 관리: SIBN의 경영진은 노련하고 경험이 풍부합니다(평균 재임 5.1 년).

이사회 구성원

이름직위재임 기간보수지분
Jeffrey Dunn
Executive Chairman18.1yrsUS$255.35k0.18%
$ 1.1m
Laura Francis
CEO & Director5.1yrsUS$7.45m1.09%
$ 6.4m
Timothy Davis
Lead Independent Director18.1yrsUS$240.35k0.12%
$ 690.4k
Gregory Hinckley
Independent Director15.3yrsUS$217.60k0.39%
$ 2.3m
Jeryl Hilleman
Independent Director6.4yrsUS$235.35k0.055%
$ 318.9k
John Freund
Independent Director13.3yrsUS$215.35k0.29%
$ 1.7m
Ralph Rashbaum
Member of Medical Advisory Board16.3yrs데이터 없음데이터 없음
Steven Garfin
Member of Medical Advisory Board16.3yrs데이터 없음데이터 없음
Frank Phillips
Member of Medical Advisory Board16.3yrs데이터 없음데이터 없음
A. Shamie
Member of Medical Advisory Board15.4yrs데이터 없음데이터 없음
Mika Nishimura
Independent Director5.2yrsUS$220.35k0.054%
$ 317.6k
Jonathan Hyde
Member of Surgeon Advisory Boardno data데이터 없음데이터 없음
15.4yrs
평균 재임 기간
68yo
평균 나이

경험이 풍부한 이사회: SIBN의 이사회는 노련하고 경험이 풍부합니다(평균 재임 15.4 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/04 09:01
종가2026/05/04 00:00
수익2025/12/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

SI-BONE, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Travis SteedBofA Global Research
Caitlin CroninCanaccord Genuity
Ross OsbornCantor Fitzgerald & Co.